Ultragenyx Pharmaceutical | RARE - 营业费用



金融业
股票价格
USD
资产
USD 1.53B
现金及等价物
USD 202.51M
销售成本
USD 29M
流动资产
USD 643.21M
流动负债
USD 340.02M
债务
USD 33.83M
EBIT
USD -114M
EBITDA
USD -156.79M
员工
1.29K
EPS每股收益
USD -1.29
股本和储备
USD 9.16M
销售毛利
USD 178M
债务利息支出
USD 19M
利息收入
USD 5.86M
贷款资金
USD 763.74M
市值
USD 1.64B
净收入
USD -129M
营业费用
USD 321M
营业利润
USD -114M
普通股股本
USD 96.44M
税前利润
USD -128M
销售收入
USD 207M
销售和管理费用
USD 89M
股票
USD 52.2M
贸易债权人
USD 40.57M
应收帐款人
USD 112.54M


营业费用 更改 日
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Immunic USD 25.73M 2.91M 2024-09
Insmed USD 513.55M 109.86M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
Kyowa Hakko Kirin JPY 109.02B 16.08B 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Xoma USD 22.84M 1.67M 2024-09